Literature DB >> 11289121

A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.

H Dosaka-Akita1, F Hommura, T Mishina, S Ogura, M Shimizu, H Katoh, Y Kawakami.   

Abstract

A large number of biological factors that seem to have important prognostic significance have been identified in non-small cell lung cancers (NSCLCs). In the present study, we have characterized expression of cyclin D1 and cyclin E in a cohort of 217 resected NSCLCs from a single institution by immunohistochemistry to analyze their expression in relation to the growth fraction determined by Ki-67 and to prognosis, and then we have constructed a risk-stratification model of cancer death by multiple biological factors in p-stage I NSCLCs. The cyclin E labeling index (LI) was significantly associated with the Ki-67 LI (r = 0.45; P < 0.001). Tumors having high-level cyclin E expression (cyclin E LI > or =30%) showed a significantly higher Ki-67 LI than tumors having low-level cyclin E expression (cyclin E LI <30%; P < 0.001), whereas positive or negative cyclin D1 expression was not associated with the Ki-67 LI (P = 0.1). Cyclin E expression was a significant and independent unfavorable prognostic factor (hazards ratio = 2.09; P = 0.03), as reported previously (Clin. Cancer Res., 6: 11-16, 2000), whereas cyclin D1 expression was not. These findings indicate different roles of cyclin D1 and cyclin E in cell proliferation and in the prognosis of NSCLCs. Furthermore, we stratified this cohort of p-stage I NSCLCs into different survival groups by using biological factors, including cyclin E, Ki-67, and ras p21, which previously we have found to be independent prognostic factors among 10 factors studied in p-stage I NSCLCs. Four groups of patients with markedly different survivals were identified with 5-year survival rates that ranged from 96% for patients with no factors altered to 41% for patients with all three factors altered (P < 0.001). This combination of biological factors was a significant and independent prognostic factor (hazards ratio = 7.94; P = 0.001).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

3.  Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G.

Authors:  Xiaoyan Xu; Shuguang Liu; Bin Lei; Wenxia Li; Ni Lin; Wenjie Sheng; Aili Huang; Hong Shen
Journal:  Mol Cell Biochem       Date:  2013-09-08       Impact factor: 3.396

4.  Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.

Authors:  N Kato; J Watanabe; T Jobo; Y Nishimura; T Fujisawa; Y Kamata; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-08       Impact factor: 4.553

Review 5.  Prognostic markers in lung cancer: is it ready for prime time?

Authors:  Chang-Qi Zhu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2014-06

6.  A Perturbation Method for Inference on Regularized Regression Estimates.

Authors:  Jessica Minnier; Lu Tian; Tianxi Cai
Journal:  J Am Stat Assoc       Date:  2012-01-24       Impact factor: 5.033

7.  Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.

Authors:  Walter N Hittelman; Diane D Liu; Jonathan M Kurie; Reuben Lotan; Jin Soo Lee; Fadlo Khuri; Heladio Ibarguen; Rodolfo C Morice; Garrett Walsh; Jack A Roth; John Minna; Jae Y Ro; Anita Broxson; Waun Ki Hong; J Jack Lee
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

8.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.

Authors:  Yan Ma; Steven Fiering; Candice Black; Xi Liu; Ziqiang Yuan; Vincent A Memoli; David J Robbins; Heather A Bentley; Gregory J Tsongalis; Eugene Demidenko; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

9.  Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Shinya Ishikawa; Jun Nakano; Sung Soo Chang; Shuji Bandoh; Nobuhiro Kanaji; Reiji Haba; Yoshio Kushida; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

10.  Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Naruhide Kimura; Shinya Ishikawa; Masaya Okuda; Shuji Bandoh; Nobuhiro Kanaji; Masato Asakura; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.